表紙
市場調查報告書

可溶性鳥甘酸環化酶:開發中產品分析

Soluble Guanylate Cyclase - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 365802
出版日期 內容資訊 英文 103 Pages
訂單完成後即時交付
價格
可溶性鳥甘酸環化酶:開發中產品分析 Soluble Guanylate Cyclase - Pipeline Review, H1 2020
出版日期: 2020年05月30日內容資訊: 英文 103 Pages
簡介

本報告提供以可溶性鳥甘酸環化酶為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

可溶性鳥甘酸環化酶 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Ironwood Pharmaceuticals, Inc.
  • Mallinckrodt Plc
  • NicOx S.A.
  • SynZyme Technologies, LLC

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2440TDB

Summary:

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Soluble guanylyl cyclase (sGC) is the known receptor for nitric oxide. Binding of nitric oxide to the heme moiety of the cyclase induces its capacity to synthesize the second messenger cGMP. Although the changes in the state of the heme moiety upon exposure of enzyme to NO and its correlation to the stimulation of sGC catalytic activity.

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) pipeline Target constitutes close to 29 molecules. Out of which approximately 26 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 6, 4 and 14 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Report covers products from therapy areas Cardiovascular, Ophthalmology, Metabolic Disorders, Respiratory, Gastrointestinal, Oncology, Central Nervous System, Dermatology, Genito Urinary System And Sex Hormones, Hematological Disorders, Infectious Disease and Musculoskeletal Disorders which include indications Glaucoma, Ocular Hypertension, Pulmonary Arterial Hypertension, Diabetic Nephropathy, Diastolic Heart Failure, Lung Disease, Open-Angle Glaucoma, Vaso-Occlusive Crisis Associated With Sickle Cell Disease, Acute Heart Failure, Acute Respiratory Distress Syndrome, Alzheimer's Disease, Asthma, Chronic Kidney Disease (Chronic Renal Failure), Chronic Thromboembolic Pulmonary Hypertension, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Coronavirus Disease 2019 (COVID-19), Critical Limb Ischemia, Cystic Fibrosis, Diabetic Foot Ulcers, Diabetic Retinopathy, Dry (Atrophic) Macular Degeneration, Ischemic Stroke, Liver Diseases, Liver Fibrosis, Mycobacterium Infections, Non-Alcoholic Steatohepatitis (NASH), Osteoporosis, Pancreatic Cancer, Pressure Ulcers, Prostate Cancer, Pulmonary Hypertension, Sickle Cell Disease, Skin Ulcers, Stroke, Systolic Heart Failure and Vascular Dementias.

The latest report Soluble Guanylate Cyclase - Pipeline Review, H1 2020, outlays comprehensive information on the Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2)
  • The report reviews Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Introduction
  • Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Overview
  • Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Therapeutics Development
  • Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Therapeutics Assessment
  • Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Companies Involved in Therapeutics Development
  • Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Drug Profiles
  • Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Dormant Products
  • Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Discontinued Products
  • Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indications, H1 2020
  • Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products under Investigation by Universities/Institutes, H1 2020
  • Products under Investigation by Universities/Institutes, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by AntiRadical Therapeutics LLC, H1 2020
  • Pipeline by Bayer AG, H1 2020
  • Pipeline by Boehringer Ingelheim International GmbH, H1 2020
  • Pipeline by Cyclerion Therapeutics Inc, H1 2020
  • Pipeline by Gurus BioPharm, H1 2020
  • Pipeline by NicOx SA, H1 2020
  • Pipeline by Novartis AG, H1 2020
  • Pipeline by Novoteris LLC, H1 2020
  • Pipeline by Toa Eiyo Ltd, H1 2020
  • Pipeline by Topadur Pharma AG, H1 2020
  • Dormant Products, H1 2020
  • Dormant Products, H1 2020 (Contd..1), H1 2020
  • Dormant Products, H1 2020 (Contd..2), H1 2020
  • Dormant Products, H1 2020 (Contd..3), H1 2020
  • Dormant Products, H1 2020 (Contd..4), H1 2020
  • Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020